Integration and Acquisition Costs

For the three and six months ended June 30, 2018, Shire recorded Integration and acquisition costs of $179.3 million and $419.0 million, respectively. These costs relate to the continued integration of Baxalta Inc. (Baxalta), which was acquired in June 2016, Takeda’s proposed acquisition of Shire, the expected sale of Shire's Oncology franchise, and the change in fair value of contingent consideration, primarily related to lanadelumab (SHP643), which was acquired from Dyax in 2016.

The Company continues its activities to integrate Baxalta. The costs associated with the integration are primarily related to facility consolidation and professional consulting fees. The Company also drove savings through the continued re-prioritization of its research and development programs and consolidation of its commercial operations. For the three and six months ended June 30, 2018 these costs include $5.9 million and $143.4 million, respectively, of asset impairments, $21.2 million and $43.1 million, respectively, of third-party professional fees, $3.1 million and $14.8 million, respectively, of expenses associated with facility consolidations, and $9.2 million and $15.0 million, respectively, of employee severance and acceleration of stock compensation. The Company expects the majority of these expenses, except for certain costs related to facility consolidations, to be paid within 12 months from the date the related expenses were incurred. The integration of Baxalta is estimated to be completed by mid to late 2019.

The following table summarizes the reserve for the Baxalta integration costs for certain types of activities during the six months ended June 30, 2018:



(In millions)	Severance and employee benefits			Lease terminations			Total
As of January 1,	$	72.9		$	56.6		$	129.5
Amount charged to integration costs	8.4			2.1			10.5
Paid/utilized	(61.8		)	(11.1		)	(72.9		)
As of June 30,	$	19.5		$	47.6		$	67.1

On May 8, 2018, the Boards of Takeda and Shire announced that they had reached an agreement on the terms of a recommended offer pursuant to which Takeda will acquire the entire issued and to be issued ordinary share capital of Shire. The closing of the acquisition is expected in the first half of 2019, subject to shareholder approval of both companies as well as the receipt of regulatory approvals. Costs associated with this recommended offer include $64.0 million of third-party professional fees and $4.0 million of employee incentives for both the three and six months ended June 30, 2018. The Company expects the majority of these expenses to be paid within 12 months from the date the related expenses were incurred.

On April 16, 2018, the Company entered into a definitive agreement with Servier to sell its Oncology franchise. Activities to conclude the sale are on track and the closing of the transaction is expected to occur in the third quarter of 2018. Costs associated with this sale include $37.5 million of third-party professional fees and $2.2 million of employee incentives for both three and six months ended June 30, 2018. The Company expects the majority of these expenses to be paid within 12 months from the date the related expenses were incurred.

In the three and six months ended June 30, 2018, $27.0 million and $45.9 million are included in Integration and acquisition costs relating to the change in fair value of contingent consideration payable mainly related to lanadelumab (SHP643).

For the three and six months ended June 30, 2017, Shire recorded Integration and acquisition costs of $343.7 million and $459.7 million, respectively, primarily related to the acquisition and integration of Baxalta and Dyax. In the three and six months ended June 30, 2017, $151.2 million and $147.7 million is included in Integration and acquisition costs relating to the change in fair value of contingent consideration payable mainly related to lanadelumab (SHP643). For the three and six months ended June 30, 2017, the Baxalta Integration and acquisition costs include $80.2 million and $117.1 million, respectively, of employee severance and acceleration of stock compensation, $50.4 million and $85.6 million, respectively, of third-party professional fees, and $17.2 million and $41.7 million, respectively, of expenses associated with facility consolidations.